Ertugliflozin, a sodium/glucose cotransporter 2 (SGLT2) inhibitor has been approved by FDA for glycemic control in adults with type 2 diabetes. Ertugliflozin has been approved as monotherapy (5-mg and 15-mg tablets) to be taken once daily.
Ertugliflozin is the fourth SGLT2 inhibitor after Canagliflozin, Dapagliflozin and Empagliflozin. Ertugliflozin has also been approved as part of two fixed-dose combinations: Ertugliflozin + DPP-4inhibitor - Sitagliptin (once daily) Ertugliflozin 5 mg and sitagliptin 100 mg Ertugliflozin 15 mg and sitagliptin 100 mg Ertugliflozin + Metformin (twice daily) Ertugliflozin 2.5 mg and metformin hydrochloride 500 mg Ertugliflozin 2.5 mg and metformin hydrochloride 1,000 mg Ertugliflozin 7.5 mg and metformin hydrochloride 500 mg Ertugliflozin 7.5 mg and metformin hydrochloride 1,000 mg Indications And Usage Ertugliflozin is indicated as an adjunct to diet…
